Date: 2014-05-23
Type of
information: Initiation of the trial
phase: 3
Announcement: initiation of the trial
Company: Eli Lilly (USA - IN)
Product: abemaciclib (LY2835219)
Action
mechanism:
- cell cycle inhibitor/cyclin dependant kinase inhibitor. Abemaciclib (LY2835219) is a cell cycle inhibitor, designed to block the growth of cancer cells by specifically inhibiting CDK 4 and 6. Although abemaciclib inhibits both CDK 4 and CDK 6, the results from the cell-free enzymatic assays have shown that it was most active against Cyclin D 1 and CDK 4.
Disease: non-small cell lung cancer (NSCLC)
Therapeutic
area: Cancer - Oncology
Country: Argentina, Austria, Brazil, Canada, China, France, Germany, Greece, Israel, Italy, Japan, Republic of Korea, Poland, Puerto Rico, Romania, Russian Federation, Spain, Taiwan, Turkey, Ukraine, USA
Trial
details:
- JUNIPER is a randomized phase 3 study of abemaciclib plus best supportive care versus erlotinib plus best supportive care in patients with stage IV non-small cell lung cancer (NSCLC) with a detectable KRAS mutation who have progressed after platinum-based chemotherapy. The main purpose of this study is to evaluate how safe and effective abemaciclib is in participants with lung cancer. (NCT02152631)
Latest
news:
- • On May 23, 2014, a Phase 3 trial sponsored by Eli Lilly was published on the NIH website ClinicalTrials.gov for abemaciclib (LY2835219) and is currently recruiting participants.
Is
general: Yes
